X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse PLETHICO PHARMA with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PLETHICO PHARMA   ACTAVIS
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
ACTAVIS
Dec-14
PLETHICO PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs39518,690-   
Low Rs3111,400-   
Sales per share (Unadj.) Rs604.43,365.5-  
Earnings per share (Unadj.) Rs32.5-420.0-  
Cash flow per share (Unadj.) Rs51.3308.8-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.67,299.6-  
Shares outstanding (eoy) m34.08265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.5 7.9%   
Avg P/E ratio x6.6-35.8 -18.3%  
P/CF ratio (eoy) x4.248.7 8.5%  
Price / Book Value ratio x0.52.1 21.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,2624,000,411 0.2%   
No. of employees `000NA21.6 0.0%   
Total wages/salary Rs m1,5960-   
Avg. sales/employee Rs ThNM41,429.5-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-5,170.0-  
INCOME DATA
Net Sales Rs m20,598894,878 2.3%  
Other income Rs m386-2,233 -17.3%   
Total revenues Rs m20,984892,644 2.4%   
Gross profit Rs m2,818114,960 2.5%  
Depreciation Rs m642193,774 0.3%   
Interest Rs m1,59328,226 5.6%   
Profit before tax Rs m969-109,273 -0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,016 0.0%   
Tax Rs m-138-5,618 2.5%   
Profit after tax Rs m1,107-111,671 -1.0%  
Gross profit margin %13.712.8 106.5%  
Effective tax rate %-14.35.1 -277.9%   
Net profit margin %5.4-12.5 -43.1%  
BALANCE SHEET DATA
Current assets Rs m18,877471,486 4.0%   
Current liabilities Rs m11,896343,852 3.5%   
Net working cap to sales %33.914.3 237.6%  
Current ratio x1.61.4 115.7%  
Inventory Days Days3658 61.9%  
Debtors Days Days19866 298.5%  
Net fixed assets Rs m9,861109,273 9.0%   
Share capital Rs m3410-   
"Free" reserves Rs m12,3310-   
Net worth Rs m16,1391,940,957 0.8%   
Long term debt Rs m4,7061,017,099 0.5%   
Total assets Rs m33,1463,557,135 0.9%  
Interest coverage x1.6-2.9 -56.0%   
Debt to equity ratio x0.30.5 55.6%  
Sales to assets ratio x0.60.3 247.0%   
Return on assets %8.1-2.3 -347.3%  
Return on equity %6.9-5.8 -119.2%  
Return on capital %12.3-3.0 -408.2%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Net fx Rs m1,2190-   
CASH FLOW
From Operations Rs m2,437153,668 1.6%  
From Investments Rs m-6,265-367,940 1.7%  
From Financial Activity Rs m2,490206,729 1.2%  
Net Cashflow Rs m-1,337-7,543 17.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.51 Rs / USD

Compare PLETHICO PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare PLETHICO PHARMA With: ALKEM LABORATORIES  TORRENT PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  BIOCON LTD  



Today's Market

Sensex Ends Volatile Day Flat; Realty Stocks Top Losers(Closing)

After opening the day in green and scaling new all-time high levels, share markets in India witnessed volatile trading activity throughout the day and ended the day flat.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Has A Bank Ever Told You Its Deposits are Riskier than Stocks? These Should Have...(The 5 Minute Wrapup)

Jul 3, 2018

Left on their own, the banks would possibly have to mark down the value of deposits by 90% to 100%.

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

The 5-Point Checklist to Save You from Toxic Stocks(Profit Hunter)

Jul 2, 2018

Worried about investing in one of the poisonous stocks that keep emerging from the woodwork? This checklist could come to your rescue

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS